N2Growth Blog

OCTOBER 26, 2023

Moreover, governance excellence is synonymous with nurturing a culture of transparency, trust, and ethical behavior. Such a board is not merely a governance powerhouse but a catalyst for innovation, decision-making sagacity, and long-term sustainability.

Succession 396

Succession Ethics Diversity Objective 396

Harvard Business Review

JUNE 9, 2017

Legitimate concerns over conflict of interest that have resulted in overly extreme preventative policies are a central cause. It is time for all parties to revisit those policies and replace them with rules that recognize both true conflicts and true confluences of interest. Insight Center. Sponsored by Optum.

Conflict of Interest 10

Conflict of Interest Pharmaceuticals Policies Industry 10

Rajesh Setty

MARCH 19, 2013

I have known Dr. William Miller (co-founder of Value Centered Innovation ) for a number of years and every conversation with him on business model innovation and beyond has been delightful and insightful. RS: What are the larger considerations to defining and innovating a business model?

Business Model 39

Business Model Innovation Banking Conflict of Interest 39

Harvard Business Review

SEPTEMBER 12, 2012

The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients. Negative results are usually not published at all.

Business Model 15

Business Model Company Pharmaceuticals Price 15

Harvard Business Review

JUNE 2, 2014

If your company puts you in charge of developing a foreign market or a new line of business, your challenges are in many ways similar to those facing a startup. But as Steve Blank, Henry Chesbrough, and others have pointed out , that advantage is offset by the daunting fact that corporate innovators have to fight a war on two fronts.

Innovation 11

Innovation Conflict of Interest Strategy System 11

Harvard Business Review

FEBRUARY 3, 2017

By that I mean that pharma companies should develop innovative treatments for pervasive unmet medical needs; avoid corruption, collusion, and other unethical marketing practices; and make sure that their products reach as many patients around the world as possible. Mitigate the risk of unethical conduct.

Reputation 8

Reputation Pharmaceuticals Price Business Model 8